MDM2 Inhibitor Intermediate Synthesis Using a Stable Vilsmeier Reagent

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing processes for preparing the MDM2 inhibitor intermediate 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (Compound A) are inefficient and lack optimization for scalability and purity.

Innovation Solution

A process involving the use of methoxymethylene-N,N-dimethyliminium methyl sulfate as a bench-stable Vilsmeier reagent for selective in situ activation of a primary alcohol intermediate, combined with specific solvents and bases like KOAc, to prepare the intermediate (DHO), which is further characterized by a crystalline form with a distinct X-ray powder diffraction pattern.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If traditional synthetic routes (e.g., Houghtening route, Kunin route) are used to prepare MDM2 inhibitors, then the target compound can be obtained, but the synthesis involves complex multi-step processes with multiple protection and deprotection steps, resulting in low overall yield and high production cost

Engineering Contradiction:
Improveoverall yieldVSAvoidsynthesis process complexity
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The synthesis route is divided into distinct modular stages: preparing the amidine intermediate, preparing the cyclopropyl carboxylic acid intermediate, and coupling them together. This segmentation allows each stage to be optimized independently and simplifies the overall process planning and execution.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent prepares and characterizes key intermediates (amidine intermediate and cyclopropyl carboxylic acid intermediate) in advance with defined purity requirements before final coupling. This preliminary action ensures that when the final coupling step is performed, the reactants are ready-to-use, eliminating the need for in-process purification and reducing overall process complexity.

Inventive Principle:
Principle #10Preliminary action

2Productivity

If traditional synthetic routes are used, then the MDM2 inhibitor can be synthesized, but multiple protection and deprotection steps are required, increasing the number of synthesis steps and reducing efficiency

Engineering Contradiction:
Improvesynthesis efficiencyVSAvoidsynthesis time
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The invention extracts and eliminates the unnecessary protection and deprotection steps from the traditional synthetic routes. By designing the synthesis pathway to proceed without these auxiliary steps, the patent directly reduces the total number of steps and the time required for synthesis while maintaining product purity.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The synthetic route enables continuous progression through the coupling reaction without interruption for protection/deprotection cycles. The amidine intermediate and cyclopropyl carboxylic acid intermediate can be coupled directly in a continuous manner, maximizing productive reaction time and eliminating wasteful standby periods between steps.

Inventive Principle:
Principle #20Continuity of useful action

3Manufacturing precision

If conventional purification methods are used during synthesis, then intermediate purity can be maintained, but the number of purification steps increases, complicating the process and reducing yield

Engineering Contradiction:
Improveintermediate purityVSAvoidpurification process complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The synthesis method is designed so that the reaction conditions themselves promote the formation of pure intermediates without requiring additional purification interventions. The coupling reaction proceeds in a manner that naturally favors the desired product formation, and the intermediates can be used directly in subsequent steps without separate purification operations.

Inventive Principle:
Principle #25Self-service

4Ease of manufacture

If existing synthetic routes are employed, then MDM2 inhibitors can be produced, but the production cost is high due to multiple steps and low yield, making it difficult to achieve cost-effective large-scale production

Engineering Contradiction:
Improveproduction costVSAvoidoverall yield
Core Design Contradiction:
Ease of manufactureVSProductivity

Solution Approach 1:

The patent optimizes reaction parameters such as solvent selection (acetonitrile, dichloromethane, or toluene), temperature ranges (0°C to room temperature), and reagent ratios to maximize yield at each step. By carefully controlling these parameters, the synthesis achieves high efficiency without requiring expensive additional steps or materials.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The process enhances the efficiency and scalability of preparing the intermediate, ensuring high purity and consistency, which is crucial for the synthesis of Compound A.

Implementation Method 1

coupling 20-24 with 15-19, wherein the coupling is performed in the presence of a coupling reagent

Methodology Applied
Scientific EffectCarbodiimide coupling: Chemical Bonding

Implementation Method 2

in the presence of a base

Methodology Applied
Scientific EffectAcid-base neutralization: Redox Reactions

Data Source

PatentEP3843733B1Process for preparing an MDM2 inhibitor intermediate
Publication Date: 2026.05.20 AMGEN INC
  • EP3843733B1 patent drawingFigure 1
  • EP3843733B1 patent drawingFigure 2
  • EP3843733B1 patent drawingFigure 3

AI summary

The present invention provides commercial processes for preparing 2- ((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-l-((S)-l-(isopropylsulfonyl)-3-methylbutan-2-yl)-3 -m ethyl-2-oxopiperi din-3 -yl)acetic acid as well as intermediates thereof.